Clinical trial
A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered [15-O]-H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Conditions Using PET Imaging (RAPID-WATER-FLOW)
NCT05134012 is registered in ClinicalTrials.gov with MedTrace Pharma A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered [15-O]-H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Conditions Using PET Imaging (RAPID-WATER-FLOW)
- Lead sponsor
- MedTrace Pharma A/S
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- May 8, 2022
- Completion date
- October 31, 2026
- Enrollment
- 215 (estimated)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.